Clinical trials: Attention Deficit Disorders With Hyperactivity
- Condition Attention Deficit Disorders With Hyperactivity
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder
A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.
A 6-week double-blind study to evaluate the safety and efficacy of Quillichew extended release chewable tablets in 4-5 year old children with attention deficit hyperactivity disorder.
- Trial name
- NCT03580005
- Testing
- methylphenidate HCl ERCT
- Sponsor
- Pfizer
Attention Deficit Disorder With Hyperactivity
NeuroLex EEG-Based ADHD Assessment Aid, Pivotal Study
The study will evaluate the effectiveness of a standardized EEG method with the intended clinical users in the intended clinical settings with the intended population (patients who would typically receive a clinician's evaluation…
- Trial name
- NEBA (NCT00595751)
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- Lexicor Medical Technology, LLC
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to determine if an investigational treatment is effective in improving the total score on the ADHD-RS-IV Preschool Version in children 4-5 years old diagnosed with ADHD.
- Trial name
- NCT03260205
- Testing
- SPD489 (Lisdexamfetamine dimesylate), SPD489
- Where
- 48 sites in United States
- Volunteers
- 199 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.
The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD.
- Trial name
- NCT00152022
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.
- Volunteers
- 412 people
- Sponsor
- Shire
Healthy Adult Participants
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult…
- Trial name
- NCT07486895
- Testing
- Centanafadine
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity
Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
The study is designed to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy (in the morning).
- Trial name
- NCT00386581
- Testing
- atomoxetine
- Where
- Russia
- Volunteers
- 105 people
- Sponsor
- Eli Lilly and Company
Adult Attention Deficit Hyperactivity Disorder
The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
A trial to assess the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder.
- Trial name
- NCT03324581
- Testing
- OPC-64005, Atomoxetine
- Where
- 26 sites in United States
- Volunteers
- 239 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children
The purpose of this study is to determine the effectiveness and safety of OROS*methylphenidate/CONCERTA* vs. immediate release methylphenidate as a treatment for ADHD specifically for those children who have behavioural…
- Trial name
- NCT00304681
- Testing
- OROS*-Methylphenidate
- Volunteers
- 147 people
- Sponsor
- Janssen-Ortho Inc., Canada
ADHD
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
- Trial name
- NCT03618030
- Testing
- PRC-063 oral capsules
- Where
- 8 sites in United States
- Volunteers
- 288 people
- Sponsor
- Purdue Pharma, Canada
ADHD
Assessing a Wearable Digital Therapy for Youth With ADHD
The purpose of this study is to evaluate and compare three different investigational wearable digital interventions to determine if they are helpful for improving symptoms and functioning in children diagnosed with…
- Trial name
- NCT05710965
- Testing
- FRx-001, FRx-003, FRx-004
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Revibe Technologies
Attention Deficit Disorder With Hyperactivity
An Effectiveness and Safety Study of CONCERTA® (Methylphenidate Hydrochloride) in the Treatment of Adolescents With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the safety and effectiveness of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) versus placebo for the treatment of Attention Deficit Hyperactivity…
- Trial name
- NCT00249353
- Testing
- methylphenidate hydrochloride
- Volunteers
- 220 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Attention Deficit Disorder With Hyperactivity
Concerta (Methylphenidate) -To-Generic Switch Study
The primary purpose of this study is to identify whether, after adjustment for confounders via stratification on a propensity score and adjustment for calendar year, the combined endpoint consisting of #1 to #4 (1.
- Trial name
- NCT02730572
- Testing
- Concerta, Concerta AG formulation, Concerta EG formulation
- Volunteers
- 1,464 people
- Sponsor
- Janssen Research & Development, LLC
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
Double blinded clinical trial placebo controlled in 153 children (planned enrollment) with recent diagnosis of ADHD. Patients will be randomized to atomoxetine or placebo arm (2:1).
- Trial name
- NCT00191945
- Testing
- Atomoxetine Hydrochloride
- Where
- 11 sites in Spain
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
Study of the what the body does to the drug in subjects with mild, moderate, and sever liver dysfunction (not working properly)
- Trial name
- NCT02795637
- Testing
- dasotraline
- Where
- 5 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD
The current study will investigate if QbMobile can be used to improve the accuracy and objective identification of reduced ADHD symptoms in tests scores once treatment has been initiated.
- Trial name
- NCT07217977
- Testing
- observational study
- Where
- 7 sites in United States
- Volunteers
- 175 people
- Sponsor
- Qbtech AB
Attention Deficit Hyperactivity Disorder
The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
This study was designed to compare Concerta Extended Release tablets with Metadate CD capsules in children with ADHD who were between 6 and 12 years old.
- Trial name
- NCT00381758
- Testing
- Methylphenidate Extended Release Capsules
- Volunteers
- 184 people
- Sponsor
- UCB Pharma
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the long-term safety and efficacy of three NRP104 doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of adults with ADHD.
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Trial name
- NCT00337285
- Testing
- Vyvanse (lisdexamfetamine dimesylate), NRP104
- Where
- 45 sites in United States
- Volunteers
- 349 people
- Sponsor
- New River Pharmaceuticals
Attention Deficit Hyperactivity Disorder
Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)
Children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who are not tolerating or not responding well to stimulant therapy will be included in this study.
- Trial name
- ADHD SWITCH (NCT00760747)
- Testing
- Atomoxetine
- Where
- 6 sites in Australia, Mexico and 1 more
- Volunteers
- 112 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers, Drug Users
A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
This single-center study will be a single-dose, randomized, double-blind, placebo- and active-controlled crossover study with a single inpatient treatment visit.
- Trial name
- NCT02144415
- Testing
- EB-1020 400 mg, EB-1020 800 mg, lisdexamfetamine 150 mg
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.